What aspects of illness influence public preferences for healthcare priority setting? A discrete choice experiment in the UK
MORRELL E. et al, (2021), PharmacoEconomics
Preferences for Medical Consultations from Online Providers: Evidence from a Discrete Choice Experiment in the United Kingdom
BUCHANAN J. et al, (2021), Applied Health Economics and Health Policy
Implementing interventions to reduce antibiotic use: A qualitative study in high-prescribing practices
BOREK A. et al, (2021), BMC Family Practice
Awareness of appropriate antibiotic use in primary care for influenza-like illness: evidence of improvement from UK population-based surveys
POUWELS K. et al, (2020), Antibiotics
MORRELL E. et al, (2020), Antibiotics
How did a Quality Premium financial incentive influence antibiotic prescribing in primary care? Views of Clinical Commissioning Group and general practice professionals
BOREK A. et al, (2020), Journal of Antimicrobial Chemotherapy
Why do hospital prescribers continue antibiotics when it is safe to stop? Results of a choice experiment survey
ROOPE L. et al, (2020), BMC Medicine
MORRELL L. et al, (2019), Trials, 2019, 297 - 297
Correction to: Will the reformed Cancer Drugs Fund address the most common types of uncertainty? An analysis of NICE cancer drug appraisals.
Morrell L. et al, (2019), BMC health services research, 19, 198 - 198
Will the reformed Cancer Drugs Fund address the most common types of uncertainty? An analysis of NICE cancer drug appraisals.
Morrell L. et al, (2018), BMC Health Serv Res, 18
Hordern JWS. et al, (2017), Biomedicine Hub
Morrell L. et al, (2017), Health Science Reports
Cancer drug funding decisions in Scotland: impact of new end-of-life, orphan and ultra-orphan processes.
Morrell L. et al, (2017), BMC health services research, 17, 613 - 613
Does the Public Prefer Health Gain for Cancer Patients? A Systematic Review of Public Views on Cancer and its Characteristics.
Morrell L. et al, (2017), PharmacoEconomics
Pricing and reimbursement experiences and insights in the European Union and the United States: Lessons learned to approach adaptive payer pathways.
Faulkner SD. et al, (2016), Clinical pharmacology and therapeutics, 100, 730 - 742